- Home
- SNTI vs ESLA Comparison
SNTI vs ESLA Comparison
Compare SNTI & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- ESLA
- Stock Information
- Founded
- SNTI 2016
- ESLA 2021
- Country
- SNTI United States
- ESLA United States
- Employees
- SNTI N/A
- ESLA N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNTI Health Care
- ESLA Health Care
- Exchange
- SNTI Nasdaq
- ESLA Nasdaq
- Market Cap
- SNTI 53.6M
- ESLA 48.9M
- IPO Year
- SNTI N/A
- ESLA N/A
- Fundamental
- Price
- SNTI $2.00
- ESLA $3.05
- Analyst Decision
- SNTI Strong Buy
- ESLA Strong Buy
- Analyst Count
- SNTI 3
- ESLA 1
- Target Price
- SNTI $9.67
- ESLA $16.00
- AVG Volume (30 Days)
- SNTI 292.3K
- ESLA 430.7K
- Earning Date
- SNTI 11-12-2025
- ESLA 11-20-2025
- Dividend Yield
- SNTI N/A
- ESLA N/A
- EPS Growth
- SNTI N/A
- ESLA N/A
- EPS
- SNTI N/A
- ESLA N/A
- Revenue
- SNTI N/A
- ESLA N/A
- Revenue This Year
- SNTI N/A
- ESLA N/A
- Revenue Next Year
- SNTI $150.00
- ESLA N/A
- P/E Ratio
- SNTI N/A
- ESLA N/A
- Revenue Growth
- SNTI N/A
- ESLA N/A
- 52 Week Low
- SNTI $1.26
- ESLA $0.70
- 52 Week High
- SNTI $16.94
- ESLA $3.09
- Technical
- Relative Strength Index (RSI)
- SNTI 53.68
- ESLA 78.22
- Support Level
- SNTI $1.92
- ESLA $2.31
- Resistance Level
- SNTI $2.29
- ESLA $2.80
- Average True Range (ATR)
- SNTI 0.20
- ESLA 0.36
- MACD
- SNTI -0.02
- ESLA 0.07
- Stochastic Oscillator
- SNTI 26.67
- ESLA 95.42
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.